Searchable abstracts of presentations at key conferences on calcified tissues

ba0005cabs.oc2.5 | Oral Communications | ECTS2016

Inhibition of BMP signalling reduces bone destruction and impacts niche maintenance in a mouse model of multiple myeloma

Gooding Sarah , Webb Siobhan , Olechnowicz Sam , Lwin Seint , Armitage Andrew , Ramasamy Karthik , Drakesmith Hal , Edwards Claire

Multiple myeloma is usually incurable, the bone marrow niche providing a protective microenvironment for quiescent tumour cells. We hypothesised that manipulation of BMP activity, a regulator of cell differentiation in the bone marrow, might affect control of tumour growth by its niche and in addition alter the lytic bone disease of myeloma. Moreover BMP signalling contributes to the hepcidin upregulation and resultant inflammatory anaemia that is characteristic of myeloma. Re...

ba0005cabs.oc4.2 | Oral Communications | ECTS2016

Bisphosphonates prevent osteolysis and muscle weakness in aromatase inhibitor-treated mice with breast cancer bone metastases

Wright Laura , Harhash Ahmed , Waning David , Mohammad Khalid , Marks Andrew , Guise Theresa

Up to half of women treated with an aromatase inhibitor (AI) for breast cancer develop muscle weakness, bone loss, and joint pain. Moreover, an elevated state of osteoclastic bone resorption has been shown to prime the bone microenvironment in ways that accelerate metastatic growth. We hypothesized that AI-induced bone loss could increase breast cancer progression in bone and exacerbate muscle weakness associated with bone metastases. Four-week female athymic nude mice underwe...

ba0006oc25 | (1) | ICCBH2017

Biochemical and physical function outcomes after 5 years of treatment with asfotase alfa in adolescents and adults with hypophosphatasia: phase 2 study results

Kishnani Priya S. , Rockman-Greenberg Cheryl , Denker Andrew E. , Moseley Scott , Whyte Michael P.

Objective: To evaluate safety and efficacy after 5 years of treatment with asfotase alfa in adolescents and adults with hypophosphatasia (HPP) in a Phase 2, open-label, randomized, dose-ranging study (NCT01163149).Methods: Treatment with subcutaneous asfotase alfa 0.3 or 0.5 mg/kg per d was compared with no treatment (control) for 6 months in patients aged 13–66 years. After 6 months, all patients (treatment and control groups) received active treat...

ba0006p086 | (1) | ICCBH2017

Feasibility and reproducibility using HRpQCTII in children and adolescents

Kent Kyla , Whalen Jessica , Strickland Ariana , Leonard Mary , Burghardt Andrew J.

We recruited 60 healthy volunteers ages 5 to 21 to perform scan-rescan precision tests on the XtremeCT II. Participants were positioned in a carbon fiber immobilization cast. iPad-based video content was used to facilitate motion-free compliance. Distal radius and tibia scans were acquired starting 2 mm proximal to the proximal margin of the growth plate or growth plate remnant. Diaphyseal radius and tibia scans were centered at an offset from the same landmark, corresponding ...

ba0006p099 | (1) | ICCBH2017

Bone strength and microarchitectural deficits in children with cystinosis

Burghardt Andrew , Kent Kyla , Long Jin , Whalen Jessica , Phelps Maira , Leonard Mary

Children with cystinosis have numerous risk factors for impaired bone accrual. We used state-of-the-art quantitative imaging of bone microarchitecture (HR-pQCT) to measure trabecular and cortical microstructure and bone strength in children and adolescents (5-20yrs) with cystinosis. We enrolled 20 cystinosis patients and recruited 34 healthy age- and gender- matched controls. Distal radius and tibia HR-pQCT scans (XtremeCT II, Scanco Medical) were acquired 2...

ba0007oc10 | (1) | ICCBH2019

Next-generation antibody-guided enzyme replacement therapy for lysosomal storage diseases

Baik Andrew , Aaron Nina , Birnbaum Matthew , Calafati Philip , Schoenherr Christopher , Economides Aris , Cygnar Katherine

Objectives: Lysosomal diseases (LDs) are a heterogenous group of 40+ genetic disorders that can affect virtually all organs and systems, including the skeletal system. They are often caused by the loss of an enzyme critical for the breakdown of macromolecules in the lysosome, leading to accumulation of these substrates and subsequent lysosomal dysfunction. Enzyme replacement therapy (ERT) is the primary treatment option for many LDs, but several issues hinder the efficacy of t...

ba0007p67 | (1) | ICCBH2019

Bone health outcomes in children and adolescents with neuromuscular disease

Biggin Andrew , Chua Verene , Wall Christie , Pacey Verity , Gray Kelly , McGee Richard , Poon Myra , Munns Craig

Objectives: To compare and contrast the natural history of osteoporosis and response to zoledronate in children and adolescents with Duchene muscular dystrophy (DMD), spinal muscular atrophy (SMA) or other congenital muscular dystrophies (CMD).Methods: A retrospective medical record review of fracture history, treatment and bone mineral densitometry of children managed at a tertiary centre in Sydney over the last 6 years.Results: A...

ba0007p146 | (1) | ICCBH2019

Does prior bisphosphonate therapy in children and adolescents with cerebral palsy alter surgical outcomes?

Fiscaletti Melissa , Loucos Robert , Jamil Kamal Abdul , Biggins Andrew , Munns Craig , Pacey Verity

Background: Children and adolescents with cerebral palsy (CP) experience musculoskeletal complications including spinal deformities, hip dysplasia and disuse osteoporosis. Bisphosphonates can improve bone mineral density, prevent fragility fractures. It is unclear if prior bisphosphonate use modifies post-operative complication in children with CP. Our aim was to compare surgical complications in children with CP with and without previous bisphosphonate treatment.<p class=...

ba0007p199 | (1) | ICCBH2019

Diversity of outcomes in randomised trials of interventions for children with osteogenesis imperfecta

McGee Richard , Wall Christie-Lee , Biggin Andrew , Pacey Verity , Poon Myra , Munns Craig

Objective: The potential for clinical trials to impact patient care may be limited if the outcomes reported vary by trial and lack direct relevance to patients. We aimed to systematically assess the scope and consistency of outcomes reported in randomised trials of interventions for children with osteogenesis imperfecta.Methods: We systematically searched for all published and unpublished randomised trials of interventions for children with osteogenesis ...

ba0007p200 | (1) | ICCBH2019

Whole body vibration training for children and adolescents with congenital myopathy

Hutchence Meghan , Pacey Verity , North Kathryn , Clarke Nigel , Rose Kristy , Biggin Andrew , Briody Julie , Munns Craig

Objectives: To evaluate the effect of 24 weeks of weight bearing vibration therapy (WBVT) on muscle strength, motor function and bone health in children with congenital myopathies.Methods: A prospective pilot study incorporating a six month observational period followed by 6 months home-based WBVT (Galileo® Pro) was undertaken. Ambulant children with congenital myopathies aged 4–16 years were eligible for inclusion. Participants were assessed a...